Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol, vol.27, pp.1-27, 2016. ,
Immunotherapy revolutionises non-small-cell lung cancer therapy: results, perspectives and new challenges, Eur. J. Cancer, vol.78, pp.16-23, 2017. ,
Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST version 1. 1-defined disease progression in clinical trials, Semin. Oncol, vol.44, pp.3-7, 2017. ,
Current Treatment algorithms for patients with metastatic non-small cell, non-squamous lung cancer, Front. Oncol, vol.7, p.38, 2017. ,
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N. Engl. J. Med, vol.373, pp.123-135, 2015. ,
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N. Engl. J. Med, vol.373, pp.1627-1639, 2015. ,
Pembrolizumab for the treatment of non-small-cell lung cancer, N. Engl. J. Med, vol.372, pp.2018-2028, 2015. ,
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial, Lancet Oncol, vol.16, pp.257-265, 2015. ,
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, vol.387, pp.1540-1550, 2016. ,
Temporal and genderrelated trends in brain metastases from lung and breast cancer, Minn. Med, vol.86, pp.32-37, 2003. ,
Summary report on the Graded Prognostic Assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases, J. Clin. Oncol, vol.30, pp.419-425, 2012. ,
EFNS guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force, Eur. J. Neurol, vol.13, pp.674-681, 2006. ,
The role of chemotherapy in the treatment of patients with brain metastases from solid tumors, Int. J. Clin. Oncol, vol.14, pp.299-306, 2009. ,
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation, Eur. Respir. J, vol.37, pp.624-631, 2011. ,
Erlotinib as secondline treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803), Ann. Oncol, vol.24, pp.993-999, 2013. ,
Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-smallcell lung cancer: groupe Français de Pneumo-Cancerologie (GFPC) Protocol 95-1, Ann. Oncol, vol.12, pp.59-67, 2001. ,
A brief report of the status of central nervous system metastasis enrollment criteria for advanced nonsmall cell lung cancer clinical trials: a review of the ClinicalTrials.gov Trial Registry, J. Thorac. Oncol, vol.11, pp.407-413, 2016. ,
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases, Lung Cancer, vol.98, pp.114-117, 2016. ,
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial, Lancet Oncol, vol.17, pp.976-983, 2016. ,